DALLAS, May 23, 2020 — Hydroxychloroquine and azithromycin may have a serious impact on the cardiovascular system and are a potentially lethal combination, according to a large analysis of a World Health Organization (WHO) database on adverse drug reactions, published yesterday in Circulation, the flagship journal of the American Heart Association.
The study, “Cardiovascular Toxicities Associated with Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database,” is an observational, retrospective meta-analysis of a WHO database encompassing more than 21 million adverse event case reports across all medication classes from more than 130 countries between November 14, 1967, and March 1, 2020, mainly before the COVID-19 pandemic.
The study compared cardiovascular adverse-drug-reactions (CV-ADRs) in patients who received hydroxychloroquine, azithromycin or the combination of both medications with all other cardiovascular medications in the database. Hydroxychloroquine and azithromycin, alone or in combination, have been proposed for treatment of COVID-19 patients.
DALLAS, May 23, 2020 — Hydroxychloroquine and azithromycin may have a serious impact on the cardiovascular system and are a potentially lethal combination, according to a large analysis of a World Health Organization (WHO) database on adverse drug reactions, published yesterday in Circulation, the flagship journal of the American Heart Association.
The study, “Cardiovascular Toxicities Associated with Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database,” is an observational, retrospective meta-analysis of a WHO database encompassing more than 21 million adverse event case reports across all medication classes from more than 130 countries between November 14, 1967, and March 1, 2020, mainly before the COVID-19 pandemic.
The study compared cardiovascular adverse-drug-reactions (CV-ADRs) in patients who received hydroxychloroquine, azithromycin or the combination of both medications with all other cardiovascular medications in the database. Hydroxychloroquine and azithromycin, alone or in combination, have been proposed for treatment of COVID-19 patients.
More of the same.